000258240 001__ 258240
000258240 005__ 20231004134645.0
000258240 0247_ $$2doi$$a10.1038/s41598-023-36653-9
000258240 0247_ $$2pmid$$apmid:37301929
000258240 0247_ $$2pmc$$apmc:PMC10257179
000258240 0247_ $$2altmetric$$aaltmetric:149871342
000258240 037__ $$aDZNE-2023-00586
000258240 041__ $$aEnglish
000258240 082__ $$a600
000258240 1001_ $$0P:(DE-2719)9000732$$aSabir, Hemmen$$b0$$eFirst author$$udzne
000258240 245__ $$aComparing the efficacy in reducing brain injury of different neuroprotective agents following neonatal hypoxia-ischemia in newborn rats: a multi-drug randomized controlled screening trial.
000258240 260__ $$a[London]$$bMacmillan Publishers Limited, part of Springer Nature$$c2023
000258240 3367_ $$2DRIVER$$aarticle
000258240 3367_ $$2DataCite$$aOutput Types/Journal article
000258240 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1688477009_1577
000258240 3367_ $$2BibTeX$$aARTICLE
000258240 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000258240 3367_ $$00$$2EndNote$$aJournal Article
000258240 520__ $$aIntrapartum hypoxia-ischemia leading to neonatal encephalopathy (NE) results in significant neonatal mortality and morbidity worldwide, with > 85% of cases occurring in low- and middle-income countries (LMIC). Therapeutic hypothermia (HT) is currently the only available safe and effective treatment of HIE in high-income countries (HIC); however, it has shown limited safety or efficacy in LMIC. Therefore, other therapies are urgently required. We aimed to compare the treatment effects of putative neuroprotective drug candidates following neonatal hypoxic-ischemic (HI) brain injury in an established P7 rat Vannucci model. We conducted the first multi-drug randomized controlled preclinical screening trial, investigating 25 potential therapeutic agents using a standardized experimental setting in which P7 rat pups were exposed to unilateral HI brain injury. The brains were analysed for unilateral hemispheric brain area loss after 7 days survival. Twenty animal experiments were performed. Eight of the 25 therapeutic agents significantly reduced brain area loss with the strongest treatment effect for Caffeine, Sonic Hedgehog Agonist (SAG) and Allopurinol, followed by Melatonin, Clemastine, ß-Hydroxybutyrate, Omegaven, and Iodide. The probability of efficacy was superior to that of HT for Caffeine, SAG, Allopurinol, Melatonin, Clemastine, ß-hydroxybutyrate, and Omegaven. We provide the results of the first systematic preclinical screening of potential neuroprotective treatments and present alternative single therapies that may be promising treatment options for HT in LMIC.
000258240 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000258240 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000258240 650_7 $$2NLM Chemicals$$aNeuroprotective Agents
000258240 650_7 $$063CZ7GJN5I$$2NLM Chemicals$$aAllopurinol
000258240 650_7 $$0JL5DK93RCL$$2NLM Chemicals$$aMelatonin
000258240 650_7 $$03G6A5W338E$$2NLM Chemicals$$aCaffeine
000258240 650_7 $$095QN29S1ID$$2NLM Chemicals$$aClemastine
000258240 650_7 $$2NLM Chemicals$$aHedgehog Proteins
000258240 650_7 $$2NLM Chemicals$$aHydroxybutyrates
000258240 650_2 $$2MeSH$$aHumans
000258240 650_2 $$2MeSH$$aInfant, Newborn
000258240 650_2 $$2MeSH$$aAnimals
000258240 650_2 $$2MeSH$$aRats
000258240 650_2 $$2MeSH$$aNeuroprotective Agents: pharmacology
000258240 650_2 $$2MeSH$$aNeuroprotective Agents: therapeutic use
000258240 650_2 $$2MeSH$$aAnimals, Newborn
000258240 650_2 $$2MeSH$$aAllopurinol: pharmacology
000258240 650_2 $$2MeSH$$aMelatonin: pharmacology
000258240 650_2 $$2MeSH$$aMelatonin: therapeutic use
000258240 650_2 $$2MeSH$$aCaffeine: pharmacology
000258240 650_2 $$2MeSH$$aClemastine: pharmacology
000258240 650_2 $$2MeSH$$aHedgehog Proteins
000258240 650_2 $$2MeSH$$aBrain Injuries: drug therapy
000258240 650_2 $$2MeSH$$aBrain
000258240 650_2 $$2MeSH$$aHypothermia, Induced: methods
000258240 650_2 $$2MeSH$$aHypoxia-Ischemia, Brain: drug therapy
000258240 650_2 $$2MeSH$$aHypoxia: drug therapy
000258240 650_2 $$2MeSH$$aHydroxybutyrates: pharmacology
000258240 650_2 $$2MeSH$$aAsphyxia Neonatorum: drug therapy
000258240 650_2 $$2MeSH$$aDisease Models, Animal
000258240 650_2 $$2MeSH$$aIschemia: therapy
000258240 7001_ $$0P:(DE-2719)9001055$$aMaes, Elke$$b1$$udzne
000258240 7001_ $$0P:(DE-2719)9000835$$aZweyer, Margit$$b2$$udzne
000258240 7001_ $$0P:(DE-2719)2811751$$aSchleehuber, Yvonne$$b3$$udzne
000258240 7001_ $$aImam, Farhad B$$b4
000258240 7001_ $$aSilverman, Jared$$b5
000258240 7001_ $$aWhite, Yasmine$$b6
000258240 7001_ $$aPang, Raymand$$b7
000258240 7001_ $$aPasca, Anca M$$b8
000258240 7001_ $$aRobertson, Nicola J$$b9
000258240 7001_ $$aMaltepe, Emin$$b10
000258240 7001_ $$0P:(DE-2719)2810557$$aBernis, Maria Eugenia$$b11$$eLast author$$udzne
000258240 773__ $$0PERI:(DE-600)2615211-3$$a10.1038/s41598-023-36653-9$$gVol. 13, no. 1, p. 9467$$n1$$p9467$$tScientific reports$$v13$$x2045-2322$$y2023
000258240 8564_ $$uhttps://pub.dzne.de/record/258240/files/DZNE-2023-00586%20SUP1.doc
000258240 8564_ $$uhttps://pub.dzne.de/record/258240/files/DZNE-2023-00586%20SUP1.docx
000258240 8564_ $$uhttps://pub.dzne.de/record/258240/files/DZNE-2023-00586%20SUP1.odt
000258240 8564_ $$uhttps://pub.dzne.de/record/258240/files/DZNE-2023-00586%20SUP1.pdf
000258240 8564_ $$uhttps://pub.dzne.de/record/258240/files/DZNE-2023-00586%20SUP2.pdf
000258240 8564_ $$uhttps://pub.dzne.de/record/258240/files/DZNE-2023-00586%20SUP3.pdf
000258240 8564_ $$uhttps://pub.dzne.de/record/258240/files/DZNE-2023-00586%20SUP4.pdf
000258240 8564_ $$uhttps://pub.dzne.de/record/258240/files/DZNE-2023-00586%20SUP2.pdf?subformat=pdfa$$xpdfa
000258240 8564_ $$uhttps://pub.dzne.de/record/258240/files/DZNE-2023-00586%20SUP3.pdf?subformat=pdfa$$xpdfa
000258240 8564_ $$uhttps://pub.dzne.de/record/258240/files/DZNE-2023-00586%20SUP4.pdf?subformat=pdfa$$xpdfa
000258240 8564_ $$uhttps://pub.dzne.de/record/258240/files/DZNE-2023-00586.pdf$$yOpenAccess
000258240 8564_ $$uhttps://pub.dzne.de/record/258240/files/DZNE-2023-00586.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000258240 909CO $$ooai:pub.dzne.de:258240$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000258240 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000732$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000258240 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001055$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000258240 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000835$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000258240 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811751$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000258240 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810557$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b11$$kDZNE
000258240 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000258240 9141_ $$y2023
000258240 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000258240 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000258240 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-08-08T09:38:07Z
000258240 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-03-30
000258240 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-03-30
000258240 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-03-30
000258240 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-03-30
000258240 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-03-30
000258240 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSCI REP-UK : 2022$$d2023-08-24
000258240 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000258240 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000258240 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-24
000258240 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:11:06Z
000258240 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:11:06Z
000258240 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T15:11:06Z
000258240 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-24
000258240 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-24
000258240 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000258240 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-24
000258240 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000258240 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2023-08-24
000258240 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-08-24
000258240 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-24
000258240 9201_ $$0I:(DE-2719)5000032$$kAG Sabir$$lNeonatal Neuroscience$$x0
000258240 980__ $$ajournal
000258240 980__ $$aVDB
000258240 980__ $$aI:(DE-2719)5000032
000258240 980__ $$aUNRESTRICTED
000258240 9801_ $$aFullTexts